Biolumpivaxin, is the world’s first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, which will help in disease surveillance as it means the experts will be able to ...

An in-house reverse-genetics generated H5N9 inactivated vaccine (SEP-22- N9) was evaluated for its vaccine efficacy in ...

The vaccine Biolumpivaxin, developed jointly by the Indian Council of Agricultural Research (ICAR) and Biovet, will enable the “differentiation of infected from vaccinated animals” (DIVA) through ...

The company claims Biolumpivaxin is the world’s first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, approved by the Central Drugs Standard Control Organization (CDSCO).

Commercial cattle farms in low-incidence bovine tuberculosis (TB) areas of England and Wales are being invited to participate in the next round of field ...

Biovet, part of Bharat Biotech, has received approval from the CDSCO for its innovative lumpy skin disease vaccine, BIOLUMPIVAXIN, for dairy cattle and buffaloes. The vaccine, developed using a ...

With VAXXITEK® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK® range with a new vaccine that protects against three severe poultry diseases: Marek's disease, Infectious Bursal ...